|
1
|
Junker K, Ficarra V, Kwon ED, Leibovich
BC, Thompson RH and Oosterwijk E: Potential role of genetic markers
in the management of kidney cancer. Eur Urol. 63:333–340. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Linehan WM and Rathmell WK: Kidney cancer.
Urol Oncol. 30:948–951. 2012. View Article : Google Scholar
|
|
4
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J
Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J
Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ricketts CJ, Morris MR, Gentle D, et al:
Genome-wide CpG island methylation analysis implicates novel genes
in the pathogenesis of renal cell carcinoma. Epigenetics.
7:278–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watt F and Molloy PL: Cytosine methylation
prevents binding to DNA of a HeLa cell transcription factor
required for optimal expression of the adenovirus major late
promote. Genes Dev. 2:1136–1143. 1988. View Article : Google Scholar
|
|
9
|
Zhu WG, Srinivasan K, Dai Z, et al:
Methylator of adjacent CpG sites affects Sp1/Sp3 binding and
activity in the p21(Cip1) promoter. Mol Cell Biol. 23:4056–4065.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morris MR, Ricketts C, Gentle D, et al:
Identification of candidate tumour suppressor genes frequently
methylated in renal cell carcinoma. Oncogene. 29:2104–2117. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reu FJ, Leaman DW, Maitra RR, et al:
Expression of RASSF1A, an epigenetically silenced tumor suppressor,
overcomes resistance to apoptosis induction by interferons. Cancer
Res. 66:2785–2793. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Q, Ying J, Zhang K, et al: Aberrant
methylation of the 8p22 tumor suppressor gene DLC1 in renal
cell carcinoma. Cancer Lett. 249:220–226. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kondratov AG, Stoliar LA, Kvasha SM, et
al: Methylation pattern of the putative tumor-suppressor gene
LRRC3B promoter in clear cell renal cell carcinomas. Mol Med
Rep. 5:509–512. 2012.PubMed/NCBI
|
|
14
|
Justice RW, Zilian O, Woods DF, Noll M and
Bryant PJ: The Drosophila tumor suppressor gene warts
encodes a homolog of human myotonic dystrophy kinase and is
required for the control of cell shape and proliferation. Genes
Dev. 9:534–546. 1995.
|
|
15
|
Ji T, Liu D, Shao W, Yang W, Wu H and Bian
X: Decreased expression of LATS1 is correlated with the progression
and prognosis of glioma. J Exp Clin Cancer Res. 31:672012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao B, Tumaneng K and Guan KL: The Hippo
pathway in organ size control, tissue regeneration and stem cell
self-renewal. Nat Cell Biol. 13:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu T, Bachman J and Lai ZC: Evidence for a
tumor suppressor role for the large tumor suppressor genes
LATS1 and LATS2 in human cancer. Genetics.
195:1193–1196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Visser-Grieve S, Zhou Z, She YM, Huang H,
Cyr TD, Xu T and Yang X: LATS1 tumor suppressor is a novel
actin-binding protein and negative regulator of actin
polymerization. Cell Res. 21:1513–1516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yabuta N, Mukai S, Okamoto A, et al:
N-terminal truncation of Lats1 causes abnormal cell growth control
and chromosomal instability. J Cell Sci. 126:508–520. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Visser S and Yang X: Identification of
LATS transcriptional targets in HeLa cells using whole human genome
oligonucleotide microarray. Gene. 449:22–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou GX, Li XY, Zhang Q, et al: Effects of
the hippo signaling pathway in human gastric cancer. Asian Pac J
Cancer Prev. 14:5199–5205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishio M, Hamada K, Kawahara K, et al:
Cancer susceptibility and embryonic lethality in Mob1a/1b
double-mutant mice. J Clin Invest. 122:4505–4518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao B, Li L, Wang L, Wang CY, Yu J and
Guan KL: Cell detachment activates the Hippo pathway via
cytoskeleton re organization to induce anoikis. Genes Dev.
26:54–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
St John MA, Tao W, Fei X, et al: Mice
deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours
and pituitary dysfunction. Nat Genet. 21:182–186. 1999.PubMed/NCBI
|
|
25
|
Yu FX and Guan KL: The Hippo pathway:
regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wierzbicki PM, Adrych K, Kartanowicz D, et
al: Underexpression of LATS1 TSG in colorectal cancer is associated
with promoter hypermethylation. World J Gastroenterol.
19:4363–4373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Steinmann K, Sandner A, Schagdarsurengin U
and Dammann RH: Frequent promoter hypermethylation of tumor-related
genes in head and neck squamous cell carcinoma. Oncol Rep.
22:1519–1526. 2009.PubMed/NCBI
|
|
28
|
Seidel C, Schagdarsurengin U, Blümke K, et
al: Frequent hypermethylation of MST1 and MST2 in soft tissue
sarcoma. Mol Carcinog. 46:865–871. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G
and Lu D: Promoter hypermethylation-mediated down-regulation of
LATS1 and LATS2 in human astrocytoma. Neurosci Res. 56:450–458.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takahashi Y, Miyoshi Y, Takahata C,
Irahara N, Taguchi T, Tamaki Y and Noguchi S: Down-regulation of
LATS1 and LATS2 mRNA expression by promoter hypermethylation and
its association with biologically aggressive phenotype in human
breast cancers. Clin Cancer Res. 11:1380–1385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tao Q, Huang H, Geiman TM, Lim CY, Fu L,
Qiu GH and Robertson KD: Defective de novo methylation of viral and
cellular DNA sequences in ICF syndrome cells. Hum Mol Genet.
11:2091–2102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hisaoka M, Tanaka A and Hashimoto H:
Molecular alterations of h-warts/LATS1 tumor suppressor in human
soft tissue sarcoma. Lab Invest. 82:1427–1435. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nishio M, Otsubo K, Maehama T, Mimori K
and Suzuki A: Capturing the mammalian Hippo: elucidating its role
in cancer. Cancer Sci. 104:1271–1277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bao Y, Hata Y, Ikeda M and Withanage K:
Mammalian Hippo pathway: from development to cancer and beyond. J
Biochem. 149:361–379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schlegelmilch K, Mohseni M, Kirak O, et
al: Yap1 acts downstream of α-catenin to control epidermal
proliferation. Cell. 144:782–795. 2011.
|
|
36
|
Moleirinho S, Chang N, Sims AH, et al:
KIBRA exhibits MST-independent functional regulation of the Hippo
signaling pathway in mammals. Oncogene. 32:1821–1830. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Angus L, Moleirinho S, Herron L, et al:
Willin/FRMD6 expression activates the Hippo signaling pathway
kinases in mammals and antagonizes oncogenic YAP. Oncogene.
31:238–250. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Badouel C and McNeill H: SnapShot: the
hippo signaling pathway. Cell. 145:484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Visser S and Yang X: LATS tumor
suppressor. a new governor of cellular homeostasis. Cell Cycle.
9:3892–3903. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Salah Z, Cohen S, Itzhaki E and Aqeilan
RI: NEDD4 E3 ligase inhibits the activity of the Hippo pathway by
targeting LATS1 for degradation. Cell Cycle. 12:3817–3823. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Serrano I, McDonald PC, Lock F, Muller WJ
and Dedhar S: Inactivation of the Hippo tumour suppressor pathway
by integrin-linked kinase. Nat Commun. 4:29762013. View Article : Google Scholar
|
|
42
|
Mo JS, Yu FX, Gong R, Brown JH and Guan
KL: Regulation of the Hippo-YAP pathway by protease-activated
receptors (PARs). Genes Dev. 26:2138–2143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu FX, Zhao B, Panupinthu N, et al:
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor
signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Noviello C, Courjal F and Theillet C: Loss
of heterozygosity on the long arm of chromosome 6 in breast cancer:
possibly four regions of deletion. Clin Cancer Res. 2:1601–1606.
1996.PubMed/NCBI
|
|
45
|
Lee EY, To H, Shew JY, Bookstein R, Scully
P and Lee WH: Inactivation of the retinoblastoma susceptibility
gene in human breast cancers. Science. 241:218–221. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Morinaga N, Shitara Y, Yanagita Y, et al:
Molecular analysis of the h-warts/LATS1 gene in human breast
cancer. Int J Oncol. 17:1125–1129. 2000.
|
|
47
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hergovich A: Regulation and functions of
mammalian LATS/NDR kinases: looking beyond canonical Hippo
signalling. Cell Biosci. 3:322013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Valis K, Prochazka L, Boura E, et al:
Hippo/Mst1 stimulates transcription of the proapoptotic mediator
NOXA in a FoxO1-dependent manner. Cancer Res. 71:946–954. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang X, Li DM, Chen W and Xu T: Human
homologue of Drosophila lats, LATS1, negatively regulate
growth by inducing G(2)/M arrest or apoptosis. Oncogene.
20:6516–6523. 2001.PubMed/NCBI
|
|
51
|
Matallanas D, Romano D, Al-Mulla F, et al:
Mutant K-Ras activation of the proapoptotic MST2 pathway is
antagonized by wild-type K-Ras. Mol Cell. 44:893–906. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hori T, Takaori-Kondo A, Kamikubo Y and
Uchiyama T: Molecular cloning of a novel human protein kinase, kpm,
that is homologous to warts/lats, a Drosophila tumor
suppressor. Oncogene. 19:3101–3109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li XJ, Park ES, Park MH and Kim SM:
3,3′-Diindolylmethane suppresses the growth of gastric cancer cells
via activation of the Hippo signaling pathway. Oncol Rep.
30:2419–2426. 2013.
|
|
54
|
Xia H, Qi H, Li Y, et al: LATS1 tumor
suppressor regulates G2/M transition and apoptosis. Oncogene.
21:1233–1241. 2002. View Article : Google Scholar : PubMed/NCBI
|
